

Drug	Generic name	Supplier (Original developer)	Indication	Price tag	Modality	Therapeutic gene	Approved nation (Approval date)	Package insert
Gendicine	rAd-p53	Benda (Shenzhen SiBionoGeneTech)	head and neck squamous cell carcinoma	<a href="#">\$387</a>	adenovirus	TP53	CN (2003/10)	-
Rexin-G	DeltaRex-G	Epeius Biotechnologies	metastatic solid tumors	<a href="#">\$0.5M</a>	retrovirus	cyclin G1	PH (2007/12)	-
Neovasculgen	PI-VEGF165	Human Stem Cells Institute	peripheral arterial disease	<a href="#">\$6,600</a>	plasmid (CMV)	VEGF165	RU (2011/12)	-
Glybera	alipogene tiparovec	uniQure	familial LPLD	<a href="#">\$1.2M</a>	AAV1	LPL	EU (2012/06)	<a href="#">link</a>
Imlygic	talimogene laherparepvec	Amgen (Biovex)	melanoma, pancreatic cancer	<a href="#">\$65K</a>	HSV1 oncolytic virus	GM-CSF	US (2015/10)	<a href="#">link</a>
Luxturna	Voretigene neparovec	Roche/Spark	retinal dystrophy (RPE65 mut)	<a href="#">\$0.85M</a>	AAV2	RPE65	US (2017/12) EU (2018/11)	<a href="#">link</a>
Zolgensma	Onasemnogene abeparovec	Novartis (AveXis/Genethon)	spinal muscular atrophy	<a href="#">\$2.1M</a>	AAV9	SMN1	US (2019/05)	<a href="#">link</a>
Upstaza	Eladocogene exuparovec	PTC Therapeutics	AADC deficiency	<a href="#">\$3.6M</a>	AAV2	AADC	EU (2022/07) US (2024/11)	<a href="#">link</a>
Hemgenix	etranacogene dezaparovec	uniQure/CSL Behring	hemophilia B	<a href="#">\$3.5M</a>	AAV5	factor IX	US (2022/11) EU (2023/02)	<a href="#">link</a>
Adstiladrin	nadofaragene firadenovec	Ferring	BCG unresponsive non-muscle-invasive bladder cancer	<a href="#">\$240K/y</a>	adenovirus	IFN $\alpha$ 2 $\beta$	US (2022/12)	<a href="#">link</a>
Elevidys	Delandistrogene moxeparovec	Sarepta	Duchenne muscular dystrophy	<a href="#">\$3.2M</a>	AAVrh74	micro-dystrophin	US (2023/06)	<a href="#">link</a>
Roctavian	Valoctocogene roxaparovec	BioMarin	hemophilia A	<a href="#">\$2.9M</a>	AAV5	factor VIII	US (2023/06)	<a href="#">link</a>
Vyjuvek	beremagene geperpavec	Krystal Biotech	dystrophic epidermolysis bullosa	<a href="#">\$630K/y</a>	HSV1	COL7A1	US (2023/05)	<a href="#">link</a>
Beqvez (Durveqtix)	fidanacogene elaparovec	Pfizer (Spark)	hemophilia B	<a href="#">\$3.5M</a>	AAVRh74var	factor IX	CA (2024/01) US (2024/04) EU (2024/07)	<a href="#">link</a>
Kebilidi	eladocogene exuparovec	PTC Therapeutics	AADC deficiency	<a href="#">\$3.71M</a>	AAV2	DDC (direct infusion to brain)	US (2024/11)	<a href="#">link</a>